The Effect of Melatonin Supplementation on Cumulus Cells and IVF Outcomes

Launched by KAOHSIUNG VETERANS GENERAL HOSPITAL. · Aug 8, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how taking melatonin, a natural supplement often used to help with sleep, might affect certain cells involved in the process of in vitro fertilization (IVF) for women aged 35 to 45. The study aims to find out if melatonin can improve the health of cumulus cells, which are important for egg development and might influence the success of IVF. If you qualify for the study, you would take melatonin for at least two months before starting your IVF treatment, and researchers will examine your cumulus cells after your eggs are retrieved to see if there are any changes.

To be eligible for this trial, you should be a woman between 35 and 45 years old with a healthy body weight. You should also be planning to undergo IVF. However, if you have certain conditions, like primary ovarian insufficiency or recent hormone therapy, you might not be able to participate. If you decide to join, you’ll be contributing to important research that could help improve IVF outcomes for women in your age group. The trial is currently recruiting participants, so it’s a great opportunity to get involved in this study.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Age 35-45 years
• • BMI 18-30 kg/m2
• • planning to undergo IVF cycles
• Exclusion Criteria:
• • Primary ovarian insufficiency
• • history of oophorectomy
• • receiving oocyte donation
• • Chromosome anomaly
• • Congenital uterine anomaly
• • Severe intrauterine adhesion
• • Malignancy
• • Using hormone therapy or supplements in recent 3 months